AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06287320 — intervention group
Intervention type: RADIATION
Intervention: concurrent or sequential chemoradiotherapy
Description: Thoracic radiation therapy(with the prescribed dose of 50-70 Gy), concurrently or sequentially combined with platinum-based doublet chemotherapy.
Study NCT06287320 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: anti-PD-1/anti-PD-L1 immune checkpoint inhibitors
Study NCT04332588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FMISO PET/MRI imaging
Description: \[18F\]FMISO PET/MRI imaging
Study NCT04989855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib plus Tislelizumab
Description: 2 cycles of Fruquintinib(F) 5mg QD d1-d14 + Tislelizumab(T) 200mg IV d1, Q3W as preoperative therapy, and F +T after TME as postoperative therapy for 6 months
Study NCT05417854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splenic Ultrasound
Description: Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
Study NCT06319105 — intervention group
Intervention type: OTHER
Intervention: Standard intervention: Offer PrEP choice
Description: This hybrid observational-implementation study will observe the implementation of a choice of oral pre-exposure prophylaxis or long-acting injectable cabotegravir for pre-exposure prophylaxis for all participants.
Study NCT04925895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic soft tissue mobilization
Description: Dynamic soft tissue mobilization will be given in the following sequence, In supine position with 90˚ flexion of knee and hip joint deep longitudinal strokes will be applied from distal to proximal direction along with the tightened area of hamstring while passively stretching the hamstring. Total 5 longitudinal strokes will be applied followed by shaking for 20 seconds. Then progressed to the next dynamic technique in the above-mentioned sequence but the patient will be asked to do leg extension actively to achieve reciprocal inhibition of the hamstring muscle. In The next step, the subject will apply a force to the therapist's hand to engage the hamstring eccentrically as the muscle will be lengthened to its end range. In that position, the therapist will apply 5 deep longitudinal strokes from the distal towards the proximal direction on tight hamstring muscles.
Study NCT04925895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive neuromuscular facilitation stretching
Description: The position of the patient will be supine lying with 90⁰ flexion of hip. Therapist will passively extend the knee joint where patient will feel a mild stretch. Then therapist will ask the patient to do knee flexion in counter resistance applied by the therapist by using about 50% of his maximum strength and isometric contraction of hamstring muscles will be achieved. Patient will maintain that isometric contraction for 8 seconds then relax on therapist command. Just after relaxation therapist will further stretch the hamstring muscle to the point of mild to moderate painless stretch and patient will hold it for 30 seconds. Three repetitions will be applied in each session.
Study NCT04925895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: application of cold pack on knee joint for 10 minutes
Study NCT04925895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: application of cold pack on knee joint for 10 minutes
Study NCT04925895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric knee strengthening excercises
Description: i. Isometric hip adductors exercises in crook lying: Two sets of 10 repetitions with a 10-seconds hold will be carried out.~ii. Isometric quadriceps strengthening exercises in supine lying: A towel roll underneath the knee joint will be used to perform this exercise. Two sets of 10 repetitions with a 10-seconds hold will be performed.
Study NCT04925895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric knee strengthening excercises
Description: i. Isometric hip adductors exercises in crook lying: Two sets of 10 repetitions with a 10-seconds hold will be carried out.~ii. Isometric quadriceps strengthening exercises in supine lying: A towel roll underneath the knee joint will be used to perform this exercise. Two sets of 10 repetitions with a 10-seconds hold will be performed.
Study NCT05779826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Play dough
Description: In the play dough group, play dough was used during the treatment of children receiving nebulizer therapy.
Study NCT05275062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM92 CAR-T cells
Description: 2.5×10\^8 CAR-T cells
Study NCT05480813 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Automated KINCISE™ impaction system versus handheld traditional mallet
Description: The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
Study NCT05480813 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Efficiency and ergonomics analysis and physical assessments
Description: Operational efficiency, ergonomic impaction, cognitive/physical/stress level evaluations,
Study NCT06420973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48+carboplatin±bevacizumab
Description: RC48 (2.5mg/kg iv on d1 , every 21d for 6 cycles) + Carboplatin (AUC5 iv on d1 every 21d for 6 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for 6 cycles) for treatment followed by RC48 (2.5mg/kg iv on d1 , every 21d for 8 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for progress ) maintenance therapy.
Study NCT06539572 — intervention group
Intervention type: PROCEDURE
Intervention: Cleft lip repair; palatoplasty; alveolar bone grafting
Description: cleft surgical treatment based on Chang Gung Craniofacial Center Protocol for cleft treatment
Study NCT05416294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary Relief
Description: The group will receive PENS treatment using Primary Relief in addition to the multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline) including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
Study NCT05416294 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Primary Relief
Description: The group will receive a sham device with multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline), including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
Study NCT06303934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: systemic therapy
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week.
Study NCT06303934 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: systemic therapy
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week.
Study NCT06303934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-Esophageal Tube Feeding
Description: Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
Study NCT06303934 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persistent Nasogastric Tube Feeding
Description: After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
Study NCT05108987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Morning
Description: Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the morning.
Study NCT05108987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Afternoon
Description: Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the afternoon.
Study NCT05108987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Afternoon
Description: Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the afternoon.
Study NCT04568226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ConquerFear Intervention
Description: ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
Study NCT04568226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control: Basic Cancer Care
Description: Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
Study NCT02590380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MESA Rail Deformity System
Description: The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the MESA Rail Deformity System.
Study NCT02590380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy Synthes USS II System
Description: The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the DePuy Synthes USS II system.
Study NCT06492096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bibloc Mandibular Advancement device
Description: Each patient received a CAD/CAM designed Bibloc Mandibular Advancement device
Study NCT05427266 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tap Block - Bupivacaine
Description: The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Standard port site infiltration) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
Study NCT05343065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlueStar 10
Description: An app that coaches individuals with diabetes and supports insulin-dosing based on continuous glucose monitor data
Study NCT05072132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal information on genetic susceptibility to arsenic toxicity
Description: The intervention groups will receive information regarding their genetic results that informs them of their arsenic metabolism efficiency. They will receive this information through a factsheet appropriate for a lay audience. The factsheet will contain information regarding arsenic metabolism and its role in removing arsenic from the body. The factsheet will describe how there is variability among individuals with respect to the efficiency with which arsenic is removed from the body, due to inherited differences in genes that affect arsenic metabolism. The factsheet describe how slower metabolizers remove arsenic slower from the body, which leads to increased in toxicity risk. The factsheet will inform participants in the intervention groups that they have been identified as a slow/fast metabolizer of arsenic based on their genes. This information will be given to participants by the URB staff, with a study physician available to address questions and concerns from the participant.
Study NCT05072132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard information on arsenic exposure reduction
Description: In this study, intervention and control groups will receive a standard informational intervention which will remind them of the effects of arsenic exposure and potential strategies that can be implemented to reduce their exposure.
Study NCT05072132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard information on arsenic exposure reduction
Description: In this study, intervention and control groups will receive a standard informational intervention which will remind them of the effects of arsenic exposure and potential strategies that can be implemented to reduce their exposure.
Study NCT05066243 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: this study is to develop a questionnaire for vulval conditions
Study NCT06317194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kTMP
Description: A new non-invasive brain stimulation tool
Study NCT06317194 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham kTMP
Description: A new non-invasive brain stimulation tool with sham setting selected
Study NCT06312072 — intervention group
Intervention type: OTHER
Intervention: No intervention; observational study
Description: No intervention; observational study
Study NCT04405050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restrata
Description: Restrata® is a novel synthetic nanofabricated scaffold (Restrata Wound Matrix (RWM), Acera Surgical, St. Louis, Missouri) has been developed which is a sterile, single-use device intended for use in the local management of wounds. The RWM is a soft, white, conformable, non-friable, absorbable matrix that acts as a protective covering for wound defects, providing a moist environment for the body's natural healing process to occur (Figure 2). The RWM is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native ECM. As a viable wrap for surgical procedures, Restrata conforms to injured tissue, can be sutured, and is arthroscopic and robotic procedure friendly.
Study NCT04405050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy (NPWT)
Description: Negative Pressure Wound Therapy (NPWT) has dramatically changed the care of complex foot wounds. Compared to standard wound care, patients with diabetic foot wounds that are treated with NPWT are 5.9 times more likely to heal and 4.4 times less likely to require amputation. NPWT involves the delivery of sub-atmospheric pressure through a vacuum pump connected to a specialized dressing to maintain a closed environment. NPWT increases perfusion to the wound, accelerates granulation tissue formation, reduces edema, and reduces bio-burden
Study NCT05751356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR128
Description: TR128 will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Starting dose is 100mg, with escalation to 500mg.
Study NCT05754346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Decongestive Therapy
Description: Complete Decongestive Therapy will include manual lymphedema drainage (self) for 20 min everyday, skin care everyday, wearing compression garment or bandages everyday and upper-extremity exercises twice a day.
Study NCT05754346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete Decongestive Therapy
Description: Complete Decongestive Therapy will include manual lymphedema drainage (self) for 20 min everyday, skin care everyday, wearing compression garment or bandages everyday and upper-extremity exercises twice a day.
Study NCT05754346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity exercises combined with diaphragmatic breathing exercises
Description: Upper-extremity exercises component of Complete Decongestive Therapy will be performed combined with diaphragmatic breathing exercises.
Study NCT04926272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-92
Description: Intravenous injection of one dose of 0.10mCi/kg(±5%) 18F-92. Each subject receive a single intravenous injection of 18F-92, and undergo PET/CT imaging within the specificed time.
Study NCT06222840 — intervention group
Intervention type: OTHER
Intervention: Electro-clinical analysis of epileptic seizures
Description: Electro-clinical analysis of epileptic seizures
Study NCT06222840 — intervention group
Intervention type: OTHER
Intervention: Electro-encephalographic cases
Description: Electro-encephalographic connectivity analysis compared to controls
Study NCT06222840 — intervention group
Intervention type: OTHER
Intervention: Clinical datas analysis
Description: Clinical datas analysis
Study NCT06222840 — intervention group
Intervention type: OTHER
Intervention: Electro-encephalographic control
Description: Electro-encephalographic connectivity analysis compared to cases
Study NCT04899232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin III
Description: Five total doses of daily 1,821 to 9,100 IUs Antithrombin III, depending on participant's weight, will be administered intravenously every other infusion day (Days 1, 3, 5, 7 and 9).
Study NCT06163612 — intervention group
Intervention type: BEHAVIORAL
Intervention: Clinical Interview
Description: A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 1 hour.
Study NCT06163612 — intervention group
Intervention type: BEHAVIORAL
Intervention: Clinical Questionnaires
Description: A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. If the participant opts to complete these questionnaires at home, they will be emailed them within 24 hours of this visit. These questionnaires will take approximately 1-2 hours.
Study NCT06163612 — intervention group
Intervention type: OTHER
Intervention: Brain Scan
Description: The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes.
Study NCT06163612 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioural Games
Description: The participant will be asked to complete two behavioural games inside the scanner. One of these games includes a monetary payout. They will be given instructions about these tasks outside of the scanner.
Study NCT06144983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvogyl
Description: In the first study group, (0.2gm) of Alvogyl paste (Septodont Inc., France), was inserted inside the alveolus, filling it entirely